1 was whether it would recognize ACCP's great potential for a broader role in influencing pharmacy' s future. Well, the message is clear: ACCP indeed has recognized this potential. Furthermore, its leadership may be ready to participate more fully with the majority of pharmacy's larger and more broadly based practitioner organizations. The White Paper makes 10 predictions about the future environment of practice, seven recommendations for the profession of pharmacy, and nine recommendations for ACCP itself. The predictions are mostly reasonable, and the recommendations are sound. All deserve serious consideration from every ACCP member.
When I express pleasure that ACCP may be ready to increase its participation, I do not mean to minimize its years of past effort. But, frankly, ACCP often has seemed a bit above the fray. I have admired ACCP from its beginning, and I admire the members whom I have gotten to know well. I was a very junior faculty member when the clinical movement started, and I saw first hand the struggle that clinical pharmacy pioneers endured, both in the clinical setting and on research faculties of pharmacy.
2, 3 I think I support most of ACCP's basic aims, at least as much as the aims of the organizations to which I belong.
The problem of a pioneer is settling down and building a town. A friend of mine with whom I discussed this editorial said it very well: ACCP is pharmacy's third standard deviation above the mean. The problem is, times change and needs change. The ACCP may be the fastest gun in the West, but the question eventually changes from, "Can you protect us from the rustlers?" to, "Can you help us build our town?" The White Paper seems to be answering in the affirmative.
Pharmacy' s leaders and most of its practitioners have a truly formidable challenge. Almost any pharmacist who has gone to more than one professional meeting or picked up a pharmacy journal in the last 10 years knows that pharmacists have to change their practices from dispensing to fuller cooperative participation in managing the outcomes of drug therapy. Furthermore, we cannot do this internally or quietly because we need the cooperation of patients and physicians if we are to improve patient outcomes. The problem, for community pharmacists especially, is equivalent to changing into a new suit of clothes while riding a bicycle down Main Street (while reading a therapeutics book).
The White Paper is good news indeed. It would be difficult to overestimate the importance of ACCP's potential contributions to helping pharmacy reach its patient care potential. This does not suggest that ACCP should lower its standards. We need ACCP to demonstrate its part of clinical excellence, and frankly, to recall us to that excellence from time to time. But pharmacy' s centrist majority needs all the help it can get, even if the work is sometimes a bit mundane.
Before the White Paper, some might have thought that ACCP's leadership had forgotten their own early struggles to establish clinical practices. Some might have wondered whether the worldwide pharmaceutical care movement was seen as a threat by some prominent clinical pharmacists. How else to understand why pharmaceutical care has been called a PHARMACOTHERAPY Volume 20, Number 8, 2000 popularization, even a "dumbing down," of clinical pharmacy by some academic clinical pharmacists. They should understand better than anyone else the struggle of most community and hospital pharmacists to change their practices. Happily, this is not the attitude conveyed by the White Paper.
I was dismayed, some years ago, during the workshop reports at an American Society of Health-System Pharmacists invitational conference on implementing pharmaceutical care. For a little while, the gulf between the pharmacists who had clinical practices and their colleagues in the same hospital who wanted help in establishing clinical practices was out in the open. The majority of community pharmacists either have to make a payroll every week or depend on a manager to make that payroll every week. They also need help from their more successful colleagues.
Pharmacists who wished they had a clinical practice have wondered why clinical pharmacists in hospitals and clinics didn't offer a hand, and why clinical faculties taught practice models that simply don't work when there is no medical record at hand. Maybe things will begin to change now.
We are all in this together. Lawmakers and policy makers are not interested in the distinctions that we are so fond of making between this and that kind of pharmacist. The centrist majority in pharmacy surely has its hands full, as it tries to reach its objective of making pharmaceutical care into the expected practice norm. Until now, it has taken fire from both the "high end," where ACCP lives, and the other end of the spectrum.
My overall enthusiasm for the White Paper was somewhat diminished in a few areas. Anyone would find some disagreeable bits in a 70-page manuscript. My strongest disagreement is with the manner in which the paper is written. True, it seems to support the idea of a wider and more forceful common cause. But the White Paper really does not acknowledge the work that has gone before, even though ACCP has been a part of much of it. ACCP members have attended strategic planning conferences, at least since Hilton Head in 1985. Many of these conferences have affected pharmacy around the world. Through the Joint Commission of Pharmacy Practitioners, ACCP has cosponsored many of them. But somehow, the tone of the paper seemed, to me, just a bit reluctant to admit that others might have seen the problem sooner and have been working on it longer. In particular, the call for a unified practice philosophy seems disingenuous, to say the least. It really conveys a sort of mean-spirited tone of "not invented here." I was amused by the White Paper's concern about the "polarization that was spawned by the entry-level degree controversy." Members of the Commission to Implement Change in Pharmaceutical Education, and other participants in that debate, will recall prominent ACCP members who were (with others, I agree) among the most polarizing combatants. I hope that these little awkward passages reflect the internal debate that is normal when position papers are being written by a committee, rather than selective memory.
The body of the White Paper includes some remarkable gaffes. One is that "pharmacy does not require visionary 'giants.'" This is really hard to understand. Perhaps it means that "giants" are not sufficient to change a profession. Fair enough, but if pharmacy did not have such visionary giants, there would be much less change, and it is safe to say there might not be a clinical pharmacy or, for that matter, an ACCP. The members of the committee who wrote the White Paper should be able to recall the same history that I remember, and should have acknowledged the debt we all owe to Don Francke, Don Brodie, Paul Parker, and others like them.
Finally, the White Paper instructs us that "future pharmacy management training must be experience based, rather than conceptual or global." I think I know what the authors may have meant, but this statement is unsupportable. Of course, if it really means "training," I would add simply that students also need management education. But since the paper does not mention management education, I assume that most people will read it as if it refers to management education as well as training. In the first place, experience-based training simply would perpetuate the good and bad management that we already have. In my opinion, this would mightily inhibit the kind of practice changes called for in the White Paper. I think that, on the contrary, pharmacists need a theoretical foundation in practice management-especially quality improvement-more than ever. This should be reinforced and supplemented by effective management training. To suggest that pharmacists need academic preparation in clinical subjects like pathophysiology and therapeutics, but not in clinical management, seems to be the sort of parochial view that we should leave behind in the 1990s.
The White Paper mentions, but seems not to develop fully, the significance of adverse outcomes of drug therapy in primary care and community medicine. This problem is widely recognized as a major problem in hospital care and among the elderly. Moreover, the problem in community practice is an order of magnitude worse than it is in hospitals. Incidentally, clinical pharmacists arguably can take a good part of the credit for this differential.
Our nation's desperate need to improve the quality of drug therapy in ambulatory care shows that the medication use process must change. Pharmacists can contribute to this at least as much as any other profession. Pharmacy' s desire for a secure future is understandable.
Intraprofessional discussions of how we should enter the future are important. However, all pharmacists should keep in mind that the future of pharmacy practice is linked inseparably to the welfare of our patients. Regardless of what pharmacy organizations do, pharmacy's professional future may depend on its ability to cooperate in the responsible provision of drug therapy.
These disagreements do not in any way diminish the real message that I took from this White Paper, and which I hope was intended. Pharmacy's organizations are closing ranks and now may move forward more confidently.
